PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature

J Clin Med. 2022 Mar 25;11(7):1829. doi: 10.3390/jcm11071829.


Although the vast majority of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging occurs in the field of prostate cancer, PSMA is also highly expressed on the cell surface of the microvasculature of several other solid tumors, including renal cell carcinoma (RCC). This makes it a potentially interesting imaging target for the staging and monitoring of RCC. The objective of this review is to provide an overview of the current evidence regarding the use of PSMA PET/Computed Tomography in RCC patients.

Keywords: PSMA PET/CT; imaging; kidney cancer; renal cell carcinoma.

Publication types

  • Review